News

Linzixuan (Rhoda) Zhang holding the medal she won in the 2024 Collegiate Inventors Competition

Rhoda Zhang Wins 2024 Collegiate Inventors Competition

MIT News

November 5, 2024

Graduate student Linzixuan (Rhoda) Zhang has won the 2024 Collegiate Inventors Competition in both the Graduate and People's Choice categories. With advisors Robert Langer and Ana Jaklenec, Zhang and KI postdoc Xin Yang are developing metal-organic frameworks and other safe, sustainable nutrient stabilizing materials to address global micronutrient deficiencies. They are also launching MOFe™ Coffee, the first iron-fortified coffee.

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Showing 281–290 of 582 stories

Adding Injury to Create Immunogenicity

MIT News

October 25, 2021

The Yaffe Lab, in collaboration with the Irvine Lab, is looking at novel ways to combine chemotherapy and radiotherapy with immunotherapy for more effective cancer treatment. In a study appearing in Science Signaling, tumor cells from mice were treated with DNA-damaging chemotherapy and re-injected back into the tumors before administering immune checkpoint blockade therapy.

Current conventions suggest that molecules released by dead or dying tumor cells can enhance immune cell response—a phenomenon known as immunogenic cell death—but here the researchers found that signals released by the still-living damaged cells were the ones inducing the greater immune response. This new approach, dubbed "immunogenic cell injury," could offer a viable treatment strategy for patients whose tumors have not previously responded to immunotherapy. The team will continue to test their approach using different drugs, dosages, and tumor types.

This work was funded in part by the Mazumdar-Shaw International Oncology Fellowship, the MIT Center for Precision Cancer Medicine, and the Charles and Marjorie Holloway Foundation.

Remembering Friend and Colleague David Livingston

MIT Koch Institute

October 20, 2021

It is with great sadness that we share the news that renowned oncologist and scientist Dr. David Livingston has passed away. As a longtime researcher in cancer genetics known also for his roles in research administration, leadership, and policy-making, Dr. Livingston was a member of the Koch Institute Scientific Advisory Board for more than a decade, and together with Tyler Jacks was the co-founder and co-leader of the Bridge Project. We are grateful for the generosity with which David shared his insight, time, and effort and offer our condolences to all of his family, friends, and colleagues.

Digging Deep to Fight Covid and Cancer

MIT News

October 14, 2021

KI member Regina Barzilay is one of the authors of a PNAS paper describing the use of deep learning models to identify synergistic drug combinations and drug-target interactions to combat Covid-19. The group's algorithmic approach is also being used to identify potential therapeutic combinations against pancreatic cancer.

Weighing Treatment Options

MIT News

October 5, 2021

The Manalis Lab’s suspended microchannel resonator platform has been adapted into a tool for predicting patient responses to specific cancer drugs. In collaboration with the laboratory of Keith Ligon at Dana-Farber Cancer Institute, researchers measured glioblastoma cells before and after treatment with the chemotherapy TMZ in order to detect tiny changes in mass which indicate treatment response. Only half of glioblastoma patients respond to TMZ, and the genetic marker for TMZ is not a reliable predictor of sensitivity for all patients. A study appearing in Cell Reports and funded in part by the MIT Center for Precision Cancer Medicine demonstrated that the method accurately predicted response to TMZ. Travera, co-founded by Manalis and Ligon, is currently testing patient samples from several cancer types with the aim of developing clinically validated lab tests.

The Case for Cancer Vaccines

MIT News

October 2, 2021

For immunotherapy to work, T cells must recognize cancerous proteins, known as neoantigens, produced by mutated cells. Research from the Jacks Lab suggests that natural competition between T cells responding to different neoantigens limits the overall ability of T cells to control tumors. The team's findings, published in Cell and discussed on the NIH Director's Blog, demonstrate that therapeutic vaccines targeting neoantigens can alleviate T cell competition and may improve patient response to immunotherapies. Read primary author Megan Burger's interview with Oncology Times here.

This work was supported in part by the Bridge Project collaboration between the Koch Institute and Dana-Farber/Harvard Cancer Center

Leading the Way for Science and Technology

MIT News

October 2, 2021

President Joe Biden has named Paula Hammond to the President’s Council of Advisors on Science and Technology. Co-chaired by MIT’s own Eric Lander and Maria Zuber, PCAST is an external advisory board providing the White House with information and policy recommendations on matters involving science, technology, education, and innovation. Hammond, a chemical engineer working in nanotechnology, brings deep expertise in solving human health and global energy challenges, as well as dedication to improving equity and representation in STEM and public health. As director Matt Vander Heiden noted in an email to the KI community, this is an incredible honor, deserving of both gratitude and congratulations. Cheers, Paula!

Cultivating a Love of Science

MIT Biology

October 1, 2021

Affection for school may not have been in Courtney JnBaptiste’s DNA growing up on a St. Lucia farm, but this KI alum found his MIT home studying microRNAs in Phil Sharp’s lab—first as a high school student and then as a graduate student. Today, he is a patent agent, helping to transform laboratory discoveries into therapeutic practices. 

The Ins and Outs of Metastasis

MIT News

September 29, 2021

The Manalis Lab, in collaboration with the Jacks Lab, uses a novel cell-counting device to measure the frequency at which tumors shed circulating tumor cells into the bloodstream and how long these CTCs remain in circulation before being cleared by the body. The team's findings, published in Nature Communications, offer a detailed view into the dynamics of metastasis and lay the groundwork for analyzing drug response in real time. This work was supported in part by the Ludwig Center at MIT.

Forest vs. Fires

MIT News

September 22, 2021

Signaling expert Forest White has begun applying his signature analytical techniques to investigate how environmental factors affect cancer development and progression. A recent modeling study challenges current thinking about carcinogenic compounds called polycyclic aromatic hydrocarbons (PAHs), which are released whenever organic matter is burned, including in wildfires, driving, and cooking. The MIT team’s findings, published in GeoHealth, suggest that the PAH historically used to inform regulatory standards may be inadequate for assessing global cancer risk.

Congratulations, Sachin!

MIT News

September 17, 2021

Cheers to graduate student Sachin Bhagchandani, the first at MIT to win the National Cancer Institute Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)! Collaborating with the Johnson, Irvine, Langer, and Spranger Labs, Bhagchandani combines immunology and polymer chemistry to develop a drug delivery system that makes certain kinds of cancer immunotherapies less toxic.